Competition and Potential Cost Reduction in the Insulin Market

This chapter explores the competition in the insulin market and its potential impact on reducing costs for patients, including the approval of biosimilar insulins and efforts by companies to manufacture and distribute low-cost insulin. It also mentions a Houston startup aiming to reduce insulin costs by 30% while acknowledging the role of pharmacy benefit managers in determining the final price patients pay.